Ticagrelor and ASA vs. ASA Only After Isolated Coronary Artery Bypass Grafting in Patients With Acute Coronary Syndrome

Prior treatment

• Previously enrolled in this study (i.e. patient now at repeat encounter)
• Concomitant surgical procedure other than CABG
• Anticoagulant treatment after the operation (e.g. warfarin, direct thrombin inhibitors (dabigatran), FXa inhibitors (rivaroxaban, apixaban, heparin, low-molecular weight heparin, fondaparinux)
• Any other indication for dual antiplatelet therapy, i.e. recent stent implantation
• Debilitating stroke within 90 days before inclusion
• Previous intracranial bleeding
• Treatment with immunosuppressants (e.g. cyclosporine and tacrolimus)
• Treatment with strong CYP3A4-inhibitors (e.g. ketoconazole, clarithromycin, nefazodone, ritonavir or atazanavir)
• Participation in any other clinical trial evaluating investigational products at the time for enrollment in this study

Other illness

• Any disorder that may interfere with drug absorption
• Any condition other than coronary artery disease with a life expectancy \<12 months
• Known chronic liver disease, renal disease requiring dialysis or bleeding disorder
• Any condition that in the opinion of the investigator may interfere with adherence to trial protocol

Other

• Discharge from the operating hospital to an ICU at another hospital
• Pregnancy or lactation
• Known intolerance or contraindication to ticagrelor or ASA
• Atrioventricular block II and III in patients without pacemaker

• Written informed consent
• Age ≥18 years
• Has undergone first time isolated CABG due to an episode of acute coronary syndrome (STEMI, NSTEMI, unstable angina) within 6 weeks before surgery